CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Prospective, interventional multicenter study evaluating adoptive cell therapy (ACT) via infusion of LN-144 (autologous TIL) followed by interleukin...
Phase 2
Seattle, Washington, United States and 56 other locations
efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma...
Phase 3
Seattle, Washington, United States and 45 other locations
The purpose of this study is to assess the patient's preference for nivolumab subcutaneous (SC) or nivolumab + relatlimab fixed-dose combination (FDC...
Phase 2
Seattle, Washington, United States and 36 other locations
artery infusion of SD-101, a TLR 9 agonist, alone or in combination with intravenous checkpoint blockade in adults with metastatic uveal melanoma...
Phase 1
Seattle, Washington, United States and 9 other locations
The purpose of this study is to determine whether nivolumab is better than ipilimumab to prevent recurrence of melanoma....
Phase 3
Seattle, Washington, United States and 135 other locations
with relapsed or refractory (R/R) metastatic or locally advanced melanoma, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC)....
Phase 1
Seattle, Washington, United States and 17 other locations
This study will test the safety of a drug called PF-08046049/SGN-BB228 in participants with melanoma and other solid tumors that are hard to...
Phase 1
Seattle, Washington, United States and 21 other locations
(PROs) of autogene cevumeran (RO7198457) plus pembrolizumab compared with pembrolizumab alone in patients with previously untreated advanced melanoma...
Phase 2
Seattle, Washington, United States and 56 other locations
placebo in participants with surgically resected high-risk Stage II melanoma. Participants in Part 1 will receive either pembrolizumab or pl...
Phase 3
Seattle, Washington, United States and 158 other locations
is safe and prevents cancer from returning in people with high-risk melanoma. Researchers want to know if V940 with pembrolizumab is better ...
Phase 3
Seattle, Washington, United States and 161 other locations
Clinical trials
Research sites
Resources
Legal